Hikal Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/znhg4mhemzqzg2nol74kz67j.pdf

Key Takeaways


Crop Protection: The Margin Reset Story

Sameer Hiremath: "It's a high-margin business with a contribution margin well in excess of the contribution margin of the current crop division and even higher than the contribution margin of the company, I would say, with a CDMO niche molecule. And the EBITDA will be well in excess of the EBITDA margins of the company."

Pharma: The FDA-Led Margin Compression

Manoj Mehrotra: "e have taken a lot of remediation measures. We also had a meeting, face-to-face meeting with U.S. FDA on June this year. They are fully satisfied with the progress what we have made. ... And if you see historically, Hikal has always had a good track record. So this 2025 inspection will be an aberration, and we will never get into this situation again."

Specialty Ingredients: Commercial Debut and the CDMO Ambition

Anish Swadi: "he target is that majority of the business is going to be CDMO rather than an own product portfolio. The own products are more to get a flavor of the market to establish ourselves to get our name out there that this is what we do."

Animal Health: Building Toward FY30


Regulatory and Operational Milestones


Guidance & Commitments

CommitmentSpecificsTimeline
Full-year revenue and profitabilityMid-teens growth in revenue and substantial improvement in profitabilityFY27
H2 performanceSignificantly better than H1 in Pharma; significant improvement in revenues and EBITDAH2 FY27
U.S. FDA reinspectionHopeful for reinspection; working toward readinessToward end of FY27
FDA clearance revenue uplift~₹150 crores annualized like-to-like revenue, ~45–46% contribution margin12 months post-clearance
Crop CDMO contract commercial launchCommercial launch with volumes growing progressively as regulatory approvals are securedToward end of FY27
Crop CDMO contract peak revenue₹50–75 crores per year at peakCalendar year 2029 / early 2030
EBITDA margin ex-remediation costCloser to 17–18%End of FY27
Animal Health revenue target~₹400 croresBy FY30
Specialty Ingredients business mixMajority CDMO rather than own productsNext 4 years
Phase II repurposing completionHuman health CDMO and animal health CDMO projectsBy end of next year

Key Metrics

MetricQ2 FY27
Revenue₹434 cr, H1 FY27: ₹837 cr
EBITDA₹45 cr, margin 10.3%; H1 FY27: ₹82 cr, margin 9.8%
PATnegative ₹6 cr, H1 FY27: negative ₹14 cr
Pharma revenue₹278 cr, H1 FY27: ₹511 cr
Pharma EBIT margin4.6%, H1 FY27: 4.0%
Crop Protection revenue₹156 cr, H1 FY27: ₹326 cr
Crop Protection EBIT marginnegative 1.5%, H1 FY27: negative 2.5%
Capital expenditure₹81 cr (H1 FY27), towards debottlenecking, inventory, regulatory upgrades and selective capacity creation
Debt-to-equity ratio0.52 as of 30th September 2026
Pharma capacity utilization60% to 70% during the quarter
U.S. FDA remediation cost~₹20 cr annualized impact on fixed operating expenses
Animal Health CDMO pipeline6 products under development
Process patents filed (R&D)9 over the last 12 months
Full-year revenue guidanceMid-teens growth, reiterated; H2 profitability expected to improve substantially